
    
      Total 200 subjects will be randomized and enrolled into four groups proportionally receiving
      experimental drug of high dose, middle dose, low dose and positive-control drug. Treatment
      duration will be 24 or 48 weeks corresponding to different HCV genotype, genotype 2,3 and
      non-genotype2,3.
    
  